StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a report published on Saturday. The brokerage issued a hold rating on the stock.
NovaBay Pharmaceuticals Stock Performance
Shares of NBY opened at $0.47 on Friday. The business’s fifty day moving average price is $0.96 and its two-hundred day moving average price is $2.64. The firm has a market capitalization of $2.32 million, a price-to-earnings ratio of 0.00 and a beta of 0.73. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $19.57.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($1.37) earnings per share (EPS) for the quarter. The firm had revenue of $2.40 million during the quarter. NovaBay Pharmaceuticals had a negative net margin of 91.86% and a negative return on equity of 744.33%. As a group, research analysts forecast that NovaBay Pharmaceuticals will post -0.17 EPS for the current year.
Hedge Funds Weigh In On NovaBay Pharmaceuticals
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Read More
- Five stocks we like better than NovaBay Pharmaceuticals
- 5 Top Rated Dividend Stocks to Consider
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- How to Invest in Blue Chip Stocks
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.